Israel

Medison Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Lead Product(s): Metreleptin

Therapeutic Area: Genetic Disease Product Name: Myalepta

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Amryt Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 08, 2021

Details:

This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.

Kamada

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Kamada Provides Update on 2021 GLASSIA Supply to Takeda

Lead Product(s): Alpha1-Proteinase Inhibitor (Human)

Therapeutic Area: Genetic Disease Product Name: Glassia

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Agreement October 07, 2020

Details:

Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.